Contact
searchSearch
HMP Global

Hidradenitis Suppurativa Topic Center

Featured Article

News
Comfort, Interest, and Therapy Choices Differ Between Hidradenitis Suppurativa Experts and Non-Experts in Complex Cases
12/20/2023
Lisa Kuhns, PhD, MD
“Although North American guidelines for HS management were recently published in 2019 from both the United States and Canadian HS Foundations, barriers to HS expertise among dermatologists still exist,” wrote coauthors.
“Although North American guidelines for HS management were recently published in 2019 from both the United States and Canadian HS Foundations, barriers to HS expertise among dermatologists still exist,” wrote coauthors.
“Although North American...
12/20/2023
First Report Managed Care
News
Two Genetic Variants Implicated in Risk of Hidradenitis Suppurativa
11/22/2023
Jolynn Tumolo
In a genetic correlation analysis, researchers found that inflammatory bowel disease, psoriasis, and type 2 diabetes may share certain genetic factors with hidradenitis suppurativa. However, additional studies are needed to shed light on...
In a genetic correlation analysis, researchers found that inflammatory bowel disease, psoriasis, and type 2 diabetes may share certain genetic factors with hidradenitis suppurativa. However, additional studies are needed to shed light on...
In a genetic correlation...
11/22/2023
First Report Managed Care
Quiz
The Impact of HS Diagnosis on Comorbidity Burden
10/27/2023
True or False: The comorbidity burden tends to decrease after HS diagnosis.
True or False: The comorbidity burden tends to decrease after HS diagnosis.
True or False: The comorbidity...
10/27/2023
First Report Managed Care
News
Costs, Comorbidity Burden High in US Patients With Hidradenitis Suppurativa
09/20/2023
Jolynn Tumolo
“Patients with HS may require comprehensive care strategies involving a multidisciplinary team of physicians to improve health while reducing health care expenditures,” researchers advised.
“Patients with HS may require comprehensive care strategies involving a multidisciplinary team of physicians to improve health while reducing health care expenditures,” researchers advised.
“Patients with HS may require...
09/20/2023
First Report Managed Care
News
HS: Targeted Therapies and Training May Improve Patient Quality of Life
08/31/2023
Danielle Sposato
Hidradenitis suppurativa treatment involves pharmacological and surgical options, but systemic treatment is restricted, with only adalimumab, an anti-TNF-a antibody, approved.
Hidradenitis suppurativa treatment involves pharmacological and surgical options, but systemic treatment is restricted, with only adalimumab, an anti-TNF-a antibody, approved.
Hidradenitis suppurativa...
08/31/2023
First Report Managed Care

Newsfeed

News
Comfort, Interest, and Therapy Choices Differ Between Hidradenitis Suppurativa Experts and Non-Experts in Complex Cases
12/20/2023
Lisa Kuhns, PhD, MD
“Although North American guidelines for HS management were recently published in 2019 from both the United States and Canadian HS Foundations, barriers to HS expertise among dermatologists still exist,” wrote coauthors.
“Although North American guidelines for HS management were recently published in 2019 from both the United States and Canadian HS Foundations, barriers to HS expertise among dermatologists still exist,” wrote coauthors.
“Although North American...
12/20/2023
First Report Managed Care
News
Two Genetic Variants Implicated in Risk of Hidradenitis Suppurativa
11/22/2023
Jolynn Tumolo
In a genetic correlation analysis, researchers found that inflammatory bowel disease, psoriasis, and type 2 diabetes may share certain genetic factors with hidradenitis suppurativa. However, additional studies are needed to shed light on...
In a genetic correlation analysis, researchers found that inflammatory bowel disease, psoriasis, and type 2 diabetes may share certain genetic factors with hidradenitis suppurativa. However, additional studies are needed to shed light on...
In a genetic correlation...
11/22/2023
First Report Managed Care
Quiz
The Impact of HS Diagnosis on Comorbidity Burden
10/27/2023
True or False: The comorbidity burden tends to decrease after HS diagnosis.
True or False: The comorbidity burden tends to decrease after HS diagnosis.
True or False: The comorbidity...
10/27/2023
First Report Managed Care
News
Costs, Comorbidity Burden High in US Patients With Hidradenitis Suppurativa
09/20/2023
Jolynn Tumolo
“Patients with HS may require comprehensive care strategies involving a multidisciplinary team of physicians to improve health while reducing health care expenditures,” researchers advised.
“Patients with HS may require comprehensive care strategies involving a multidisciplinary team of physicians to improve health while reducing health care expenditures,” researchers advised.
“Patients with HS may require...
09/20/2023
First Report Managed Care
News
HS: Targeted Therapies and Training May Improve Patient Quality of Life
08/31/2023
Danielle Sposato
Hidradenitis suppurativa treatment involves pharmacological and surgical options, but systemic treatment is restricted, with only adalimumab, an anti-TNF-a antibody, approved.
Hidradenitis suppurativa treatment involves pharmacological and surgical options, but systemic treatment is restricted, with only adalimumab, an anti-TNF-a antibody, approved.
Hidradenitis suppurativa...
08/31/2023
First Report Managed Care
News
FDA Issues Final Guidance on Biosimilar Prior Approval Supplements
09/10/2025
Grace Taylor, MS, MA
The US Food and Drug Administration (FDA) has finalized guidance clarifying 6 categories of biosimilar prior approval supplements, setting review goals that could shape timelines for new indications and payer coverage decisions.
The US Food and Drug Administration (FDA) has finalized guidance clarifying 6 categories of biosimilar prior approval supplements, setting review goals that could shape timelines for new indications and payer coverage decisions.
The US Food and Drug...
09/10/2025
First Report Managed Care
News
High Health Care Burden Among People with Hemophilia A Experiencing Bleeding or Joint Complications
09/10/2025
Juliet Gallagher
New real-world evidence shows that people with hemophilia A who experience bleeding or joint complications face significantly higher health care utilization and comorbidity burden.
New real-world evidence shows that people with hemophilia A who experience bleeding or joint complications face significantly higher health care utilization and comorbidity burden.
New real-world evidence shows...
09/10/2025
First Report Managed Care
Usmani Headshot
Conference Coverage
Rethinking the Risk: Evolving Strategies for High-Risk Smoldering Myeloma at SOHO 2025
09/08/2025
Saad Z. Usmani, MD, FACP
Dr Saad Usmani, chief of the myeloma service at Memorial Sloan Kettering Cancer Center, explores the evolving debate on early intervention for high-risk smoldering multiple myeloma, highlighting pivotal trial data and its potential to reshape...
Dr Saad Usmani, chief of the myeloma service at Memorial Sloan Kettering Cancer Center, explores the evolving debate on early intervention for high-risk smoldering multiple myeloma, highlighting pivotal trial data and its potential to reshape...
Dr Saad Usmani, chief of the...
09/08/2025
First Report Managed Care
Martin
Conference Coverage
What’s Next in Multiple Myeloma: Smoldering, High-Risk, and Frontline Therapy
09/03/2025
Thomas G. Martin, III, MD
Dr Thomas Martin previews his SOHO 2025 session and explores the pressing next questions in multiple myeloma, including when to treat smoldering disease, how to better define and manage high-risk patients, and how innovations like bispecifics...
Dr Thomas Martin previews his SOHO 2025 session and explores the pressing next questions in multiple myeloma, including when to treat smoldering disease, how to better define and manage high-risk patients, and how innovations like bispecifics...
Dr Thomas Martin previews his...
09/03/2025
First Report Managed Care
Raje Headshot
Conference Coverage
CAR T-Cell Therapy in Myeloma: A New Era of Early Intervention
09/02/2025
Noopur S. Raje, MD
At SOHO 2025, Dr Noopur Raje will present a cutting-edge overview of CAR T-cell therapy in multiple myeloma, highlighting long-term efficacy data, novel targets like GPRC5D, emerging dual-targeting and in vivo CAR strategies, and the evolving...
At SOHO 2025, Dr Noopur Raje will present a cutting-edge overview of CAR T-cell therapy in multiple myeloma, highlighting long-term efficacy data, novel targets like GPRC5D, emerging dual-targeting and in vivo CAR strategies, and the evolving...
At SOHO 2025, Dr Noopur Raje...
09/02/2025
First Report Managed Care
News
Confronting the HIV Epidemic: Addressing Gaps in Access, Adherence, and Equity
09/02/2025
Juliet Gallagher
At a recent AMCP conference, health care leaders Maria Lopes, MD, and Steve Cohen, MD, highlighted the persistent and unique challenges of HIV management in the US, emphasizing that despite medical advancements, HIV remains classified as an...
At a recent AMCP conference, health care leaders Maria Lopes, MD, and Steve Cohen, MD, highlighted the persistent and unique challenges of HIV management in the US, emphasizing that despite medical advancements, HIV remains classified as an...
At a recent AMCP conference,...
09/02/2025
First Report Managed Care
News
Industry Payments and Their Role in MS Drug Selection Among High-Volume Prescribers
08/28/2025
Juliet Gallagher
A recent observational study explored the prevalence of industry payments to neurologists who prescribe multiple sclerosis (MS) disease-modifying therapies (DMTs), uncovering significant associations between such payments and prescribing...
A recent observational study explored the prevalence of industry payments to neurologists who prescribe multiple sclerosis (MS) disease-modifying therapies (DMTs), uncovering significant associations between such payments and prescribing...
A recent observational study...
08/28/2025
First Report Managed Care
News
Medicare Advantage Plans See Double-Digit Satisfaction Drop as Medical Costs Soar
08/22/2025
Juliet Gallagher
Member satisfaction with Medicare Advantage (MA) plans has seen a significant decline, according to J.D. Power’s 2025 report, reflecting a broader set of financial and policy pressures now facing the MA landscape.
Member satisfaction with Medicare Advantage (MA) plans has seen a significant decline, according to J.D. Power’s 2025 report, reflecting a broader set of financial and policy pressures now facing the MA landscape.
Member satisfaction with...
08/22/2025
First Report Managed Care
News
Expanding Assertive Community Treatment to Transform Care for Complex Patients
08/20/2025
Lisa Kuhns, PhD, MD
A new study shows that health systems can rely on assertive community treatment (ACT), which has strong evidence supporting its effectiveness for treating the most complex, least engaged patients.
A new study shows that health systems can rely on assertive community treatment (ACT), which has strong evidence supporting its effectiveness for treating the most complex, least engaged patients.
A new study shows that health...
08/20/2025
First Report Managed Care
News
AAM White Paper Spotlights Legislative Path to Breaking Biosimilar Patent Barriers
08/18/2025
Grace Taylor, MS, MA
A recent white paper from the Association for Accessible Medicines exposes how brand-name drug patent tactics block biosimilar access and urges Congress to act on 3 key reforms to lower drug costs.
A recent white paper from the Association for Accessible Medicines exposes how brand-name drug patent tactics block biosimilar access and urges Congress to act on 3 key reforms to lower drug costs.
A recent white paper from the...
08/18/2025
First Report Managed Care

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use